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Background: Interleukin 6 is an important biomarker for dis-
tinguishing high-risk and low-risk patients, and is a constituent of 
the Nutrition Risk in the Critically III (NUTRIC) Score. Studies have 
indicated the beneficial effects of vitamin C on lowering IL-6 levels 
and reducing cytokine storm. However, there is still controversy 
about the exact effect, appropriate route, and dose of vitamin C 
usage. This meta-analysis was conducted to evaluate the current 
evidence base relating to vitamin C intervention on decreasing IL-6 
levels. 
Methods: A systematic search was performed in PubMed, Scopus, 
Google Scholar, and Cochran databases, from database inception to 
July 3rd 2021, to obtain any possible randomized clinical trial for 
inclusion. After screening and removing unrelated and duplicate 
articles, 24 eligible articles remained for statistical analysis. 
Results: We found a significant lowering effect of vitamin C sup-
plementation on IL-6 levels via peroral (PO) (WMD ¼ -0.29 pg/l, 
* Corresponding author. Tel.: þ989126654577. 
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95% CI [-0.42, -0.16], P<0.0001) and intravenous (IV) routes with 
(WMD ¼ -7.99 pg/l, 95% CI [-8.36, -7.62], P<0.0001). 
Conclusions: Vitamin C, at doses of 250e1000 mg/day and for less 
than one week of treatment, regardless of the route of adminis-
tration, reduces IL-6 levels in participants. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of 
European Society for Clinical Nutrition and Metabolism. This is an 
open access article under the CC BY license (http:// 
creativecommons.org/licenses/by/4.0/). 
1. Introduction 
Inflammatory responses triggered by rapid viral replication and cellular destruction can employ 
macrophages and monocytes and provoke the release of cytokines and chemokines. Subsequently, 
cytokines and chemokines activate immune responses, leading to cytokine storms and other metabolic 
exacerbations [1]. Among cytokines, Interleukin-6 (IL-6) is reported to be significantly associated with 
a high risk of the development of severe illness conditions [2e4]. Furthermore, IL-6 is an important 
biomarker in Nutrition Risk in the Critically Ill (NUTRIC) Score [5,6] and stimulates the production of 
acute-phase proteins in different inflammatory conditions [7]. Serum IL-6 levels in normal healthy 
people is 5e15 pg/ml [8], however, Yang and colleagues' study on rheumatoid arthritis patients showed 
that IL-6 levels can raise to 102 pg/ml in this inflammatory condition [9]. In cytokine storm syndrome, 
the levels of IL-6 can raise to 1000 pg/ml [10], and clinical improvement has been observed following 
reducing the IL-6 levels with IL-6 receptor antagonist [11]. After IL-6 is produced in the injury area in 
the initial phase of inflammation, it is conducted to the liver via the blood circulation, followed by the 
quick induction of a wide range of acute-phase proteins like C-reactive protein (CRP), serum amyloid A 
[12], fibrinogen, haptoglobin, and a1-antichymotrypsin [13]. Also, this cytokine can elicit chronic 
inflammation by the employment of monocytes to the zone of inflammation [14]. 
Vitamin C has anti-oxidant activity, provides support for the immune system [15,16], exerts antiviral 
characteristics [17,18], enhances neutrophil's phagocytic capacity, chemotaxis, and supports lympho-
cyte proliferation [1,19,20]. During sepsis, plasma levels of vitamin C are notably depleted or even not 
measurable [21e23]. Studies have shown that vitamin C can impede the production of IL-6 [23,24], and 
has potent effects on diminishing inflammatory status [25,26]. 
However, to our knowledge, no meta-analysis has examined the impacts of the dose, duration, and 
administration route of vitamin C supplementation on IL-6 levels in patients with severe respiratory 
illness and other conditions. We conducted this systematic review and meta-analysis to evaluate this 
effect of vitamin C and determine the appropriate dose, duration, and administration route of vitamin C 
usage for this purpose. 
2. Methods 
We completed this study conforming to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines [27]. This study sought to assess the probable mechanism of the advanta-
geous effects of vitamin C through decreasing IL-6 concentrations in patients and to determine the 
appropriate dose, duration, and administration route of vitamin C usage for this purpose. PubMed, 
Google Scholar, Scopus, and Cochrane databases were searched from database inception to 3rd July 
2021. Using “AND” and “OR” Boolean operators, we searched the following search terms: (“Sodium 
Ascorbic Acid” OR “L-Ascorbic Acid” OR “Acid, L-Ascorbic” OR “L Ascorbic Acid” OR “Vitamin C” OR 
“Ascorbate” AND “Interleukin-6” OR “IL6” OR “B-Cell Stimulatory Factor” OR “B-Cell Stimulatory Factor-
2” OR “IL-6”). 
Among the studies, all randomized clinical trials (RCTs) that were conducted in diverse population 
groups including children, schoolchildren, adults, males, and females; used vitamin C as intervention; 
had measured IL-6 levels (reported mean and standard deviation or standard error); and had placebo 
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or control group were included in this study. No date, language, country, or route of administration 
restriction was applied. Animal studies, cell culture experiments, in vitro supplementation, secondary 
studies, studies that had used fruit juice instead of vitamin C, co-interventions of vitamin C with 
another nutrient or active substance, editorials, commentaries, case reports, and studies without the 
full-text accessibility were not reviewed. 
Articles were reviewed based on the title, abstract, and full text, independently, by three authors 
(MG, SS, and FK), and any instances of disagreement were resolved by consensus with the senior author 
(KDj). We displayed the selection process in Figure 1. 
Habbu's checklist [28] was applied for qualitative assessment of the studies. Nineteen items are 
included in this checklist. If all criteria were present, the maximum mark of nineteen was achieved. 
Studies with scores lower than twelve were excluded from the study. Therefore, the minimum and the 
maximum scores were twelve and nineteen, respectively. 
Figure 1. Literature search and filtering of studies according to the PRISMA flow diagrams. 
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Statistical analyses were carried out using Stata version fourteen (Stata Corporation) software. The 
effect size was used for quantitative measurement of the magnitude of the mean difference between 
groups and 95% confidence intervals (CI) were calculated. Statistical heterogeneity was assessed with I2 
between 0 and 100%. We considered I2 ¼ 0%, without heterogeneity; I2 ≤ 25%, low heterogeneity; I2 < 
50%, moderate heterogeneity; and I2 > 75%, high heterogeneity [29]. To discern the source of hetero-
geneity, for groups, we performed subgroup analysis based on dose, duration, and conditions of 
vitamin C administration. To further assess causes of heterogeneity, a sensitivity analysis was done, in 
which the consequential deletion of individual studies was performed to examine the power of a single 
study on the overall effect of vitamin C usage on IL-6 levels. The risk of bias was evaluated using Stata 
software. Random effects meta-regression was used to explain the influence of age on the effectiveness 
of vitamin C for lowering IL-6 levels. 
3. Results 
According to the specified search criteria, 10504 articles were obtained, including 1208 articles from 
Scopus, 8296 articles from PubMed, 995 articles from Cochrane, and five articles from Google Scholar. 
After deleting duplicate articles, 10399 articles remained. Subsequently, screening was done on the 
remaining articles according to the form prepared, considering the Population, Intervention, Com-
parison, Outcome and Study design (PICOS) framework. Finally, twenty-four eligible articles were 
included in our systematic review and meta-analysis, eighteen articles for peroral and six articles for 
intravenous administration (Figure 1). 
3.1. Characteristics of included studies 
The studies included 801 participants, aged 20e68 years, from four continents; most studies were 
conducted in Europe and Asia. Baseline sample sizes ranged from 8 - 68 participants. Specifications of 
included articles are described in Table 1. Six studies are included for IV and eighteen studies are 
included for PO, respectively. The places of studies were in Iran (n¼6), UK(n¼6), US (n¼3), Spain (n¼2), 
Africa (n¼2), Greece (n¼1), Mexico (n¼1), Palestine (n¼1), Egypt (n¼1), and Sweden (n¼1). The 
conditions of patients that studies were carried out were in athletes, diabetes mellitus (DM), DM with 
obesity, DM with cardiovascular disease (CVD), depression, atrial fibrillation (AF), coronary artery 
bypass surgery (CABG), and ischemic reperfusion injury. The duration of studies was from one day in 
athletes, before and after exercise, up to 60 days in depressed people. 
3.2. Effect of vitamin C supplementation on plasma ascorbic acid levels 
Seventeen out of twenty-four included studies had measured plasma ascorbic acid levels before and 
after vitamin C supplementation. Analysis showed a significant (P¼0.000) increase of plasma ascorbic 
acid levels after vitamin C supplementation (WMD ¼ 33.86 mm/L, 95% CI [33.80, 33.93], (Figure 2). in 
subgroup analysis by dosage, it showed that all supplemented doses of vitamin C (except 1500 mg/d) 
have increased significantly plasma ascorbic acid levels. 
3.3. Effect of vitamin C supplementation on IL-6 levels in oral route 
The primary analysis on peroral studies showed a significant effect (P<0.0001) of vitamin C on IL-6 
levels (WMD ¼ -0.29 pg/l, 95% CI [-0.42, -0.16]. Furthermore, we found low heterogeneity (I2 ¼ 19.6%), 
(Figure 3). In the sensitivity analysis for finding the source of heterogeneity, there was no significant 
heterogeneity between studies (Figure 4). Therefore, subgroups analysis was done based on predefined 
criteria including the dose of vitamin C, duration of the treatment, and patients' conditions. 
In dosage subgroup analysis, significant negative association was observed at low doses 200e250 
mg/d, 400e500 mg/d and 1000 mg/d (WMD ¼ -0.91 pg/ml, 95% CI ¼ [ -1.44, -0.37], P <0.001; WMD ¼ 
-0.22 pg/ml, 95% CI ¼ [ -0.38, -0.05], P<0.01 and WMD ¼ -0.58 pg/ml, 95% CI ¼ [ -0.92, -0.24], P<0.001), 
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Figure 4. Sensitivity analysis for finding the weight of studies. In subgroup by duration, 7 up to 10 days supplementation pooled 
together. 
In subgroup analysis by duration, a significant negative association was observed in short term (less 
than one week) and long term (in 8 weeks) vitamin C supplementation (WMD ¼ -0.29 pg/ml, 95% CI ¼ [ 
-0.50, -0.08], P<0.008); and WMD ¼ -0.68 pg/ml, 95% CI ¼ [ -0.96, -0.39], P<0.0001), respectively 
(Appendix 2). 
Also, subgroup analysis by condition of patients showed a significant effect of vitamin C on DM [30], 
DM þ obese, and athletes patients (WMD ¼ -0.88 pg/ml, 95% CI ¼ [ -1.40, -0.36], P<0.001; WMD ¼ -0.61 
pg/ml, 95% CI ¼ [ -0.96, -0.26], P<0.001 and WMD ¼ -0.22 pg/ml, 95% CI ¼ [ -0.39, -0.05], P<0.01), 
respectively (Appendix 3). 
Moreover, the dose-response analysis showed that the lower doses of vitamin C have the greatest 
effect on IL-6. The trend of significance decreased by increasing the dosage of vitamin C. Furthermore, 
at doses higher than the highest dose of vitamin C (1500e2000 mg/d), the increase of vitamin C 
concentration did not change IL-6 plasma levels (Figure 5). Finally, the regression analysis by age did 
not illustrate a significant association between age variable and plasma IL-6 concentration (P¼ 0.23) 
(Appendix 4). 
Egger and Begg's analysis did not demonstrate a significant bias to report (95%CI: -0.639, 0.417, 
P¼0.66). The funnel plot of studies did not show any significant publication bias (Figure 6). 
3.4. Effect of vitamin C supplementation on IL-6 levels in intravenous route 
Primary analysis on the included manuscripts that used vitamin C intravenously showed a signif-
icant negative association between vitamin C supplementation and plasma IL-6 concentration (WMD 
¼ -7.97 pg/l, 95% CI [-8.34, -7.60], P<0.0001). Furthermore, we noted moderate heterogeneity (I2 ¼ 
70.3%) (Figure 7). 
Subgroup analysis by dosage was performed in two categories; greater than 1500 mg/d (shown with 
number 2) and lower than 1500 mg/d (shown with number 1). Subgroup analysis by dosages showed 
significant association between intravenous vitamin C supplementation and IL-6 plasma concentration 
in lower than 1500 mg/d (WMD ¼ -7.98 pg/l, 95% CI [-8.35, -7.60], P<0.0001) (Appendix 5). 
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Figure 5. Efficacy of dose-response of vitamin C supplementation on reducing IL-6 levels. 
Figure 6. Funnel plot analysis for finding possible bias in the report. 
Subgroup analysis by patients' condition demonstrated that vitamin C supplementation signifi-
cantly decreased IL-6 plasma concentration in sepsis, ischemic reperfusion surgery, and BDD patients 
(WMD ¼ -302.60 pg/ml, 95% CI ¼ [ -510.85, -94.34], P<0.004); (WMD ¼ -7.98 pg/ml, 95% CI ¼ [ -8.35, 
-7.61], P<0.0001) and (WMD ¼ -28.37 pg/ml, 95% CI ¼ [ -48.09, -8.65], P<0.005), respectively 
(Appendix 6). 
The Egger test did not show any significant bias in the report (95% CI: -4.02, 2.65, P ¼0.56). 
4. Discussion 
This systematic review and meta-analysis evaluated the current evidence base relating to vitamin C 
intervention on decreasing IL-6 levels in inflammatory diseases, and determined the appropriate dose, 
duration, and administration route of vitamin C usage for this purpose. We found that vitamin C has a 
prominent and statistically significant lowering effect on IL-6 levels via the oral route in Diabetic 
9 
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Figure 7. Efficacy of vitamin C on reducing IL-6 levels in studies that supplemented Vitamin C intravenously. 
Mellitus patients, athletes, and inflammatory conditions. The most effective dosage was 200e500 and 
1000 mg/d via the oral route. Also, in the intravenous route, we found a significant effect in dosages 
lower than 1500 mg/d in sepsis, ischemic reperfusion surgery, and BDD conditions. 
In dosage subgroup analysis, a significant inverse association was observed at low doses. A D. 
Gutierrez et al. performed a study in DM patients, and found that 500 up to 1000 mg/d vitamin C 
supplementation in short durations has an anti-atherosclerotic effect in diabetic patients [31]. More-
over, I Ferron-Elma et al. found that 450 mg/d vitamin C supplementation significantly can decrease 
plasma IL-6 concentration in patients with abdominal surgery and sepsis conditions [32]. Furthermore, 
Hiedra R et al. administered vitamin C intravenously at a dose of 1 g every 8 h for 3 days and observed a 
significant decrease in inflammatory markers in COVID-19 patients [33]. Jouybar et al. performed a 
study on Coronary Artery Bypass Graft Surgery patients with 3-gram vitamin C continuously over 
12e18 hours, however they did not see any association between vitamin C and IL-6 levels in higher 
dosages [37]. Nevertheless, our finding did not confirm the finding of Cheng et al. [34] who adminis-
tered high doses of intravenous vitamin C (10e20 g/day and 1500 mg/kg/day) [34]. Notably, overdoses 
of vitamin C can have adverse effects, such as kidney stones and diarrhea [35]. Moreover, oxalate 
nephropathy due to administration of high doses of vitamin C has been reported in 2 patients with 
COVID-19 [36]. The average daily requirement for vitamin C is 75 mg for females and 90 mg for males, 
whilst the tolerable upper level of vitamin C is 2 gr orally per day for adults [37]. Due to poor absorption 
of vitamin C orally, it is assumed that higher doses must be administered intravenously. Intravenous 
administration is suitable for intensive care patients because near all of them have pre-existing 
intravenous lines. On the other hand, gastrointestinal problems and difficulty in swallowing are 
common among ICU patients, which can interfere with drug absorption [38]. 
Subgroup analysis based on duration demonstrated the highest effect in durations <1 week and 8 
weeks' duration, respectively. Contrary to our findings, short durations (less than one week) of vitamin 
C treatment were carried out by Nakhostin et al. and were not effective on lowering IL-6 levels in 
inflammatory states [39]. Our results showed that, in athletes, DM, and patients that were undergoing 
surgical procedures, vitamin C had a significant reducing effect on IL-6 levels. This finding shows that 
the indication of vitamin C for lowering IL-6 levels may be more effective in some medical conditions 
than others. 
The mechanism of decrease of IL-6 levels by vitamin C is attributed to its antioxidant properties and 
inhibitory function on IL-6 producing monocytes. During lipopolysaccharide (LPS)-induced sepsis, 
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which is brought about by oxidative damage, production of NF-kB is increased, and this transcription 
factor plays an important role in the overexpression of pro-inflammatory cytokines during sepsis. 
Indeed, vitamin C can lead to a decreased production of pro-inflammatory cytokines [23]. 
Accessible data shows that increased levels of IL-6 are notably coupled with adverse clinical con-
sequences, admission in ICU, ARDS, and death in COVID-19 patients [40]. Regarding the possibility of 
the development of cytokine storm syndrome in the course of the COVID-19 [41,42], and the beneficial 
effects of vitamin C on the alleviation of inflammation in cytokine storm syndrome [43e45], the results 
of this study could be extrapolated to COVID-19 patients. Undoubtedly, among the currently available 
drugs, vitamin C is a suitable and logical option for use to alleviate ARDS [34,46]. Moreover, IL-6 is a 
biomarker that reduces appetite [47] and increases cachexia in sepsis conditions [48]. 
To our knowledge, this is the first meta-analysis on the effects of vitamin C administration on IL-6 
levels. Additionally, included studies in our meta-analysis were from nearly all continents of the world 
and performed predefined subgroup analysis. However, this meta-analysis possesses some limitations. 
While most of the studies have measured plasma levels of IL-6 by ELISA method, only eight studies 
have reported the type of anticoagulant (EDTA) used in the test tubes for collecting blood samples. A 
study by Biancotto et al. showed a variation in cytokines levels between serum and plasma samples, 
and that measurement of some cytokines has been affected by diverse anticoagulants used in pre-
paring plasma samples [49]. Not measuring vitamin C plasma concentration before and after the 
intervention and not defining the time interval between the last dose of vitamin C and measuring 
plasma IL-6 levels were limitations that were defined in some included studies. However, this is 
beyond the control of the present study, but does, nevertheless, highlight the need for adequate time 
interval definitions in subsequent studies. 
Conclusion 
We found that vitamin C at doses of 250e1000 mg/day; in treatment durations less than one week; 
in intravenous and peroral administration; and in sepsis, Diabetic Mellitus, athletes, BDD, and reper-
fusion surgical patients, reduces IL-6 levels. 
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